Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

RBC Capital analyst Ben Hendrix maintained a Buy rating on Elevance Health (ELV – Research Report) today and set a price target of $478.00. The ...

Barclays raised the firm’s price target on Elevance Health (ELV) to $522 from $512 and keeps an Overweight rating on the shares following the ...

The stock's rise snapped a four-day losing streak.

The health insurer posted revenue of $48.89 billion in the period. Its adjusted revenue was $48.77 billion, also topping Street forecasts. Seventeen analysts surveyed by Zacks expected $46.03 billion.